SELLAS Closed Up 156.36%, Then Proposed a $150 Million Stock Offering

By
CTOL Staff Reporter
1 min read

REGAL delivered a meaningful survival benefit, but SELLAS is seeking fresh equity capital before the FDA settles the route from clinical success to approval.

At $24.89, SELLAS Life Sciences had a spectacular trading day. At $19.15, it had a more complicated one. Those were its intraday high and closing share price on 17 November 2026, when Nasdaq recorded a 156.36% closing gain from $7.47. After the bell, SELLAS proposed a $150 million common stock offering. We would pass at the close. Its vaccine data earned a re-rating, but at $19.15 the stock prices in an FDA path we expect to be harder than bulls anticipate.

SELLAS won the clinical argument with REGAL, its Phase 3 trial of the leukemia vaccine galinpepimut-S. Eligible patients were in second or later complete remission and unable to receive an allogeneic stem cell transplant, a narrower group than a generic cancer-vaccine headline suggests. According to its clinical announcement, median overall survival reached 24.0 months with GPS against 14.7 months on the investigator's choice of treatment. The 24.0 minus 14.7 difference is 9.3 months. That survival difference changes the investment case.

REGAL randomized 126 patients equally between GPS and the comparison treatment in an open-label design. Its prespecified primary overall-survival endpoint was met: a hazard ratio of 0.59 means 41% lower death risk, with a two-sided p-value of 0.035. At the 60-death interim, the independent monitoring committee recommended continuing without modifications in January 2025. The final analysis followed the 80-death threshold announced on 28 October 2026. The trial lowered clinical failure risk for an investor.

The stock market delivered the other victory, in a form that management could try to spend. Catalyst Capitalization is what happens when a positive trial increases the market price of a company's equity before regulators decide whether that trial is sufficient for approval. At the Nasdaq close, $19.15 replaced the previous $7.47; the intraday high of $24.89 over $7.47, less one, was 233.2%. A higher quotation offers financing power without putting cash in the company's account.

The distinction is worth dollars, not just vocabulary. Using the 203,527,833 shares outstanding on 30 September 2026, $7.47 a share implied about $1.52 billion of equity value; $19.15 implied about $3.90 billion. Holding that historical share count constant, $3.90 billion less $1.52 billion is about $2.38 billion of added market value in one session. SELLAS sought a small portion of that increase in cash through its preliminary prospectus. The proposition is attractive for the seller precisely because the buyer is paying after the clinical re-rating.

Its 30 September balance sheet recorded $134.7 million of cash and equivalents and $22.4 million used in operations over nine months. In a scenario where the entire proposed $150 million is raised at $19.15 a share, $150 million divided by $19.15 means about 7.83 million new shares, or 3.8% of the September count. Cash would become $134.7 million plus $150 million, or $284.7 million before fees. These are scenario proceeds, not a completed sale. The company gains flexibility while existing holders surrender a portion of future gains.

Why raise money with that cash balance? Success changes what a biotech prepares to spend. Raising at a stronger share price buys time for the regulatory stage while asking shareholders to finance a result the FDA still has to assess. A sensible corporate financing choice and an attractive entry price for a new investor are separate decisions. That is the asymmetry: newly expensive shares are useful currency for SELLAS, while buyers pay that price for every remaining obstacle.

The bullish interpretation is more compelling than a caricature of excited traders. SELLAS chief executive Angelos Stergiou said REGAL demonstrated “a statistically significant and clinically meaningful improvement in overall survival” in the company's statement. The primary endpoint was death, the analysis waited for 80 deaths, and patients were randomized rather than merely observed. Survival is a harder outcome to distort than a subjective assessment, despite the open-label design. A 9.3-month median advantage gives the planned first-half 2027 BLA submission a clinical rationale, while illustrative 3.8% issuance at the closing price makes the financing cost look manageable.

Buying at $19.15 on that schedule has a coherent rationale. A 41% lower death risk reduces one huge source of uncertainty. The proposed $150 million gives the program financing with relatively modest illustrative dilution. If the FDA agrees that REGAL supplies an adequate efficacy package, both clinical and financing risk have fallen before the first-half 2027 submission. That mechanism explains why a large re-rating is rational.

The dispute is whether REGAL supplies enough efficacy evidence for the FDA to accept. SELLAS describes its first-half 2027 BLA plan as “subject to agreement with the U.S. Food and Drug Administration”. That condition falls inside the bulls' 2027 timetable. On that same first-half 2027 horizon, REGAL offers 126 randomized patients and p=0.035; the FDA will decide the required efficacy evidence. The bullish bet is specific: REGAL alone will suffice for the 2027 filing, with the observed survival benefit doing the regulatory work. That is the same regulatory decision on which both sides are betting.

Dendreon offers an uncomfortable comparison rather than a prediction. In its 2007 announcement, its randomized Provenge trial had the same 41% reduction in death risk and a stronger p-value of 0.010. An FDA advisory committee voted 13 to 4 for efficacy and 17 to 0 for safety. On 8 May 2007, the agency nevertheless issued a Complete Response Letter that “requested additional clinical data in support of the efficacy claim.” Even a favorable committee vote left Dendreon needing more evidence before approval.

Provenge treated prostate cancer in a double-blind, placebo-controlled trial; REGAL is open-label and compares GPS with an investigator's choice of treatment in leukemia maintenance. Those differences prevent a prediction from analogy. The relevant comparison is narrower: the FDA sought more efficacy evidence despite a 41% mortality-risk reduction and p=0.010. REGAL has the same 41% reduction with p=0.035 on the proposed first-half 2027 regulatory path. Raising capital buys time, while the agency controls the evidence threshold.

After the announcement of the proposed offering, Nasdaq quoted SELLAS at $16.80 at 5:28 p.m. ET on 17 November 2026, down 12.27% from its regular close. The vaccine's trial data had not changed during those hours. Investors now faced shares proposed for issuance against the elevated price. Catalyst Capitalization can favor the company while leaving new investors paying for an FDA decision still ahead.

We would pass at $19.15. We would be wrong if, by the end of June 2027, an SEC filing or company announcement records a submitted GPS BLA with favorable FDA feedback that REGAL's efficacy evidence suffices without another pivotal trial.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines. The cover photo is computer generated art for illustrative purposes only; not indicative of factual content. If you believe this article infringes upon copyright rights, please do not hesitate to report it by sending an email to us. Your vigilance and cooperation are invaluable in helping us maintain a respectful and legally compliant community.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings

We use cookies on our website to enable certain functions, to provide more relevant information to you and to optimize your experience on our website. Further information can be found in our Privacy Policy and our Terms of Service . Mandatory information can be found in the legal notice